Prevail grabs $75M A round in the hunt for new gene therapies to stop the destruction caused by Parkinson's
Another biotech upstart is coming along to compete in the fast-growing arena of gene therapy development for neurodegenerative diseases.
Just a couple of weeks after AbbVie tied up with Voyager on a gene therapy program for Alzheimer’s, Prevail Therapeutics is debuting today with a $75 million A round and a mission to go after a disease-modifying approach to Parkinson’s disease. The biotech was seeded by OrbiMed and the Silverstein Foundation.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters